Progenics Pharmaceuticals, Inc. develops innovative medicines and other technologies to identify, target and treat cancer. Their pipeline includes: (1) therapeutic agents designed to precisely target cancer (AZEDRA® and 1095); (2) PSMA-targeted imaging agents for prostate cancer (1404 and PyLTM); and (3) imaging analysis tools. Our first commercial product, RELISTOR® (methylnaltrexone bromide) for opioid-induced constipation, is partnered with Valeant. Progenics Pharmaceuticals, Inc. was incorporated in the State of Delaware in 1986.

This site uses cookies and other tracking technologies to assist with navigation and your ability to provide feedback, analyze your use of products and services, assist with our promotional and marketing efforts.